%0 Journal Article
%T Dabigatran como posibilidad terap¨¦utica en el s¨ªndrome de trombocitopenia inducida por heparina tipo II Dabigatran as a therapeutic possibility in heparin-induced thrombocytopenia type II
%A F.J. Anniccherico
%A J.L. Alonso
%A M. Urbieta
%A S. P¨¦rez Ricarte
%J Anales del Sistema Sanitario de Navarra
%D 2012
%I Gobierno de Navarra. Departamento de Salud
%X El s¨ªndrome de trombocitopenia inducido por heparina (HIT) con una incidencia del 0,2-0,5 % en pacientes expuestos a heparina durante m¨¢s de 4 d¨ªas, es producido por una alteraci¨®n inmune con formaci¨®n de anticuerpos frente al complejo heparina-factor 4 plaquetario, que presenta un amplio espectro de manifestaciones cl¨ªnicas: siendo la trombocitopenia, los fen¨®menos tromb¨®ticos arteriales/venosos y la necrosis cut¨¢nea los m¨¢s frecuentes. Hasta el momento actual, lepirudina, recientemente suspendida y argatroban (inhibidores directos de la trombina) son los f¨¢rmacos aprobados y habitualmente usados en el tratamiento, suministrados de forma parenteral. El dabigatran, un nuevo f¨¢rmaco anticoagulante, inhibidor directo y reversible de la trombina te¨®ricamente podr¨ªa ser un f¨¢rmaco empleado en el tratamiento del HIT. Seg¨²n la bibliograf¨ªa consultada presentamos el primer caso de HIT tratada con dabigatran en la literatura m¨¦dica. The syndrome of heparin-induced thrombocytopenia (HIT), with an incidence of 0.2-0.5% in patients exposed to heparin for more than 4 days, is produced by an immune alteration with the formation of antibodies against the heparin platelet factor 4 complex. It presents a wide spectrum of clinical manifestations, the most frequent of which are thrombocytopenia, thrombotic arterial-venous phenomena, and cutaneous necrosis. Up to the present, lepiridin, recently suspended, and argatroban (direct thrombin inhibitors) have been the approved medicines normally used in treatment, administered in parenteral form. Dabigatran, a new anticoagulant medicine that is a direct and reversible thrombin inhibitor, could theoretically be a medicine employed in treating HIT. According to the bibliography consulted we are presenting the first case of HIT treated with dabigatran in the medical literature.
%K S¨ªndrome de trombocitopenia
%K Dabigatran etexilato
%K Tratamiento
%K Heparin-induced trombocitopenia
%K Dabigatran etexilate
%K Treatment
%U http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272012000300024